Here are the latest developments on tirzepatide from reputable sources:
Headline: New data show persistence on Wegovy and Zepbound (tirzepatide) after a year in the US. Implication: real-world use remains stable as availability and coverage improve. This updates the understanding of how long patients stay on tirzepatide-based therapies in typical practice.[1]
Key trial update: SUMMIT trial findings indicate tirzepatide can improve outcomes for obese patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing the risk of adverse heart failure events and cardiovascular death and improving quality of life and exercise tolerance. This broadens potential indications beyond weight management and diabetes.[3][5]
Maintenance/weight management: SURMOUNT-4 explored maintenance after weight loss with tirzepatide, showing a higher rate of adverse events with ongoing tirzepatide versus placebo in the double-blind phase but providing important safety data for long-term use in weight management. This informs long-term treatment planning and monitoring.[2]
Obesity-related cancer signals: A mouse study presented at ENDO 2025 suggested tirzepatide may slow obesity-associated breast cancer growth in preclinical models, indicating potential additional benefits worth watching as human data emerge. These are early signals requiring confirmation in humans.[4]
Diabetes and weight management approvals: Tirzepatide (Mounjaro for diabetes; Zepbound for obesity) continues to be evaluated in various settings, with ongoing research into its broader cardiovascular and metabolic effects and potential expansion of indications.[6][7]
Related cardiovascular insights: SUMMIT and other trials highlight potential cardiovascular benefits beyond glycemic control, reinforcing tirzepatide’s role in comprehensive metabolic risk reduction for some patients.[5]
If you’d like, I can pull more detailed summaries from specific articles or compile a quick one-page update with key trial names, populations, outcomes, and dates. I can also search for any regulatory decisions in major markets (e.g., US, EU, India) on approvals or labeling for tirzepatide in 2026.
Citations:
Research Highlights: In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had ...
newsroom.heart.orgThe anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
www.endocrine.orgFind Tirzepatide Weight Loss Latest News, Videos & Pictures on Tirzepatide Weight Loss and see latest updates, news, information from NDTV.COM. Explore more on Tirzepatide Weight Loss.
www.ndtv.comHaving medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
www.endocrine.orgTirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.
www.nyp.orgDharam J. Kumbhani, MD, SM, FACC
www.acc.orgtirzepatide Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. tirzepatide Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.comFDA approval for use of tirzepatide for chronic weight management could come this year, drugmaker Eli Lilly said.
www.cbsnews.comThis randomized clinical trial examines the effect of tirzepatide on the maintenance of weight reduction.
jamanetwork.com"The SUMMIT trial showed that the combined GIP/GLP1 receptor agonist Tirzepatide reduces the combined endpoint of death and heart failure events in patients with obesity-related [HFpEF]," says Kramer. "This expands the indication for this drug beyond weight loss and treating diabetes. Cardiologists now have an ever-expanding armamentarium to treat HFpEF."
www.acc.org